|
1
|
Pastor JC, de la Rúa ER and Martín F:
Proliferative vitreoretinopathy: risk factors and pathobiology.
Prog Retin Eye Res. 21:127–144. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hartnett ME: The effects of oxygen
stresses on the development of features of severe retinopathy of
prematurity: knowledge from the 50/10 OIR model. Doc Ophthalmol.
120:25–39. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Penn JS: Retinal and Choroidal
Angiogenesis. Springer; Dordrecht: pp. 1192008
|
|
4
|
Näpänkangas U, Lindqvist N, Lindholm D and
Hallböök F: Rat retinal ganglion cells upregulate the pro-apoptotic
BH3-only protein Bim after optic nerve transection. Brain Res Mol
Brain Res. 120:30–37. 2003.PubMed/NCBI
|
|
5
|
Zhang Z, Qin X, Zhao X, Tong N, Gong Y,
Zhang W and Wu X: Valproic acid regulates antioxidant enzymes and
prevents ischemia/reperfusion injury in the rat retina. Curr Eye
Res. 37:429–437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cellerino A, Bähr M and Isenmann S:
Apoptosis in the developing visual system. Cell Tissue Res.
301:53–69. 2000. View Article : Google Scholar
|
|
7
|
Ozaki H, Yu AY, Della N, Ozaki K, Luna JD,
Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL and
Campochiaro PA: Hypoxia inducible factor-1alpha is increased in
ischemic retina: temporal and spatial correlation with VEGF
expression. Invest Ophthalmol Vis Sci. 40:182–189. 1999.PubMed/NCBI
|
|
8
|
Joussen AM, Murata T, Tsujikawa A,
Kirchhof B, Bursell SE and Adamis AP: Leukocyte-mediated
endothelial cell injury and death in the diabetic retina. Am J
Pathol. 158:147–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barouch FC, Miyamoto K, Allport JR, Fujita
K, Bursell SE, Aiello LP, Luscinskas FW and Adamis AP:
Integrin-mediated neutrophil adhesion and retinal leukostasis in
diabetes. Invest Ophthalmol Vis Sci. 41:1153–1158. 2000.PubMed/NCBI
|
|
10
|
Rothlein R, Dustin ML, Marlin SD and
Springer TA: A human intercellular adhesion molecule (ICAM-1)
distinct from LFA-1. J Immunol. 137:1270–1274. 1986.
|
|
11
|
Samarin S and Nusrat A: Regulation of
epithelial apical junctional complex by Rho family GTPases. Front
Biosci. 14:1129–1142. 2007.PubMed/NCBI
|
|
12
|
Smith A, Bracke M, Leitinger B, Porter JC
and Hogg N: LFA-1-induced T cell migration on ICAM-1 involves
regulation of MLCK-mediated attachment and ROCK-dependent
detachment. J Cell Sci. 116:3123–3133. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leung T, Chen XQ, Manser E and Lim L: The
p160 RhoA-binding kinase ROK alpha is a member of a kinase family
and is involved in the reorganization of the cytoskeleton. Mol Cell
Biol. 16:5313–5327. 1996.PubMed/NCBI
|
|
14
|
Riento K and Ridley AJ: Rocks:
multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol.
4:446–456. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Amano M, Nakayama M and Kaibuchi K:
Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell
polarity. Cytoskeleton (Hoboken). 67:545–554. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Warner SJ and Longmore GD: Distinct
functions for Rho1 in maintaining adherens junctions and apical
tension in remodeling epithelia. J Cell Biol. 185:1111–1125. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brady DC, Alan JK, Madigan JP, Fanning AS
and Cox AD: The transforming Rho family GTPase Wrch-1 disrupts
epithelial cell tight junctions and epithelial morphogenesis. Mol
Cell Biol. 29:1035–1049. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Olson MF: Applications for ROCK kinase
inhibition. Curr Opin Cell Biol. 20:242–248. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abman SH: Recent advances in the
pathogenesis and treatment of persistent pulmonary hypertension of
the newborn. Neonatology. 91:283–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Budzyn K, Marley PD and Sobey CG:
Targeting Rho and Rho-kinase in the treatment of cardiovascular
disease. Trends Pharmacol Sci. 27:97–104. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimokawa H: Rho-kinase as a novel
therapeutic target in treatment of cardiovascular diseases. J
Cardiovasc Pharmacol. 39:319–327. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hata Y, Miura M, Nakao S, et al:
Antiangiogenic properties of fasudil, a potent Rho-Kinase
inhibitor. Jpn J Ophthalmol. 52:16–23. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bryan BA, Dennstedt E, Mitchell DC, et al:
RhoA/ROCK signaling is essential for multiple aspects of
VEGF-mediated angiogenesis. FASEB J. 24:3186–3195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arita R, Hata Y, Nakao S, et al: Rho
kinase inhibition by fasudil ameliorates diabetes-induced
microvascular damage. Diabetes. 58:215–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yin L, Morishige K, Takahashi T, et al:
Fasudil inhibits vascular endothelial growth factor-induced
angiogenesis in vitro and in vivo. Mol Cancer Ther. 6:1517–1125.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Penn JS, Tolman BL and Lowery LA: Variable
oxygen exposure causes preretinal neovascularization in the newborn
rat. Invest Ophthalmol Vis Sci. 34:576–585. 1993.PubMed/NCBI
|
|
27
|
Kim WT and Suh ES: Retinal protective
effects of resveratrol via modulation of nitric oxide synthase on
oxygen-induced retinopathy. Korean J Ophthalmol. 24:108–118. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sharp FR, Ran R, Lu A, et al: Hypoxic
preconditioning protects against ischemic brain injury. NeuroRx.
1:26–35. 2004. View Article : Google Scholar : PubMed/NCBI
|
